GSA Capital Partners LLP Increases Position in Guardant Health, Inc. $GH

GSA Capital Partners LLP raised its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 155.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,982 shares of the company’s stock after purchasing an additional 13,378 shares during the period. GSA Capital Partners LLP’s holdings in Guardant Health were worth $1,373,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in GH. PNC Financial Services Group Inc. increased its position in Guardant Health by 8.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock valued at $251,000 after buying an additional 307 shares in the last quarter. Assetmark Inc. grew its stake in shares of Guardant Health by 18,838.6% in the third quarter. Assetmark Inc. now owns 13,257 shares of the company’s stock worth $828,000 after acquiring an additional 13,187 shares during the last quarter. Caprock Group LLC bought a new position in shares of Guardant Health during the third quarter valued at $532,000. Navellier & Associates Inc. purchased a new position in shares of Guardant Health in the 3rd quarter worth about $484,000. Finally, Candriam S.C.A. boosted its stake in Guardant Health by 0.7% in the 3rd quarter. Candriam S.C.A. now owns 171,753 shares of the company’s stock worth $10,731,000 after purchasing an additional 1,231 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Performance

GH stock opened at $107.42 on Thursday. The company’s fifty day moving average price is $106.57 and its 200-day moving average price is $85.39. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74. The company has a market capitalization of $13.54 billion, a PE ratio of -33.46 and a beta of 1.63.

Insider Activity at Guardant Health

In related news, CEO Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the transaction, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This trade represents a 37.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,511 shares of company stock worth $45,580,887 in the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on GH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Canaccord Genuity Group upped their price objective on Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Morgan Stanley increased their target price on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Robert W. Baird initiated coverage on Guardant Health in a research note on Tuesday. They issued an “outperform” rating and a $120.00 price target for the company. Finally, Evercore set a $105.00 price objective on Guardant Health and gave the company an “in-line” rating in a research report on Monday, January 5th. Twenty-two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $107.45.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.